Mannkind Corp. (MNKD)
NASDAQ:MNKD
Earnings Data
Report Date
May 13, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
>-0.01Last Year’s EPS
0.04Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveys a predominantly positive outlook: the company reported record quarterly and annual revenues, strong and accelerating growth for newly acquired Furoscix, Afrezza commercial momentum with regulatory and label progress (including pediatric PDUFA), predictable royalty and supply cash flows from Tyvaso DPI, and advancement of a potentially high-impact MNKD-201 program. Near-term challenges include integration and commercialization investments that pressure margins in 2026, seasonality for Furoscix in Q1, regulatory execution risks around PDUFAs, and some uncertainty around future supply volumes from United Therapeutics. Overall, the positives (diversified growth drivers, clear near-term catalysts, and improving adjusted profitability) outweigh the manageable risks called out on the call.Company Guidance
Record Quarterly and Annual Revenue
Q4 2025 total revenue of $112 million, up 46% year-over-year; full-year 2025 total revenue of $349 million, up 22% year-over-year. Management reported a 5-year CAGR of ~46% to nearly $350M and a stated path to a >$450M revenue run-rate in 2026.
Furoscix Rapid Growth After Acquisition
Furoscix Q4 net sales $23.3 million (management) representing 91% year-over-year growth; full-year 2025 net sales $70.4 million. The team shipped nearly as many units in Q4 as in all of 2024, expanded the sales force from ~80 to ~160 reps, and projects a 2026 CVR range of $110–$120 million.
Afrezza Commercial Momentum and Regulatory Progress
Afrezza Q4 U.S. net sales ~$22–23 million (management/CFO figures) representing ~22–25% year-over-year growth; full-year global net sales ~$74.6–75 million (16% YoY growth per CFO). First commercial shipment to Cipla (India) completed. FDA label change approved clarifying starting bolus dose; dose trial showed a 58% reduction in 2-hour postprandial glucose excursions with the higher Afrezza dose. Pediatric indication accepted with PDUFA date May 29, 2026.
Tyvaso DPI Revenue and Royalty Predictability
Q4 royalty revenue $34 million, up 24% YoY; full-year royalty revenue $128 million, up 25% YoY. Management expects over $350 million in royalties over the next 36 months and highlighted a revised supply agreement providing multi-year minimum orders (CFO: manufacturing revenues ~ $100M in 2025; expectation of similar levels for next 2 years and an approximate $50M annual floor in later committed years). Net royalty economics reported at ~9% post-transaction, providing predictable cash flow.
Completed Strategic Acquisition and Commercial Infrastructure Build
Acquisition of scPharmaceuticals (Furoscix) completed in Q4 2025; integration cited as smooth. Company doubled sales rep footprint (~80 to ~160), deployed key account managers for hospital pull-through, activated endocrine team to cover nephrology, and increased marketing spend in support of ReadyFlow Autoinjector and Furoscix growth.
Non-GAAP Profitability and Improved Full-Year Results
Q4 2025 non-GAAP adjusted net income of $1.5 million (GAAP net loss $15.9M); full-year 2025 non-GAAP adjusted net income $59.5 million and GAAP net income $5.9 million, reflecting improved profitability on an adjusted basis despite acquisition-related and noncash amortization impacts.
Multiple Upcoming Regulatory and Clinical Milestones
Key near-term catalysts include Afrezza pediatric PDUFA (May 29, 2026) and Furoscix ReadyFlow Autoinjector PDUFA (July 26, 2026). Clinical program MNKD-201 (Nintedanib DPI) advancing: U.S. Phase Ib enrolling with top-line data expected H2 2026 and global Phase II initiation expected next quarter.
Afrezza Pediatric Market Opportunity Signals
New market research: ~50% of HCPs cite eliminating mealtime injections as primary adoption driver; ~66% of pediatric endocrinologists likely to prescribe; ~25% would consider using Afrezza in newly diagnosed type 1 patients. Management estimates pediatric share potential of 23–37%, noting every 10% share historically equates to ~ $150M in net revenue opportunity.
MNKD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
MNKD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $3.50 | $3.24 | -7.43% |
Nov 05, 2025 | $5.48 | $6.06 | +10.58% |
Aug 06, 2025 | $3.99 | $3.46 | -13.16% |
May 08, 2025 | $4.85 | $4.63 | -4.54% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Mannkind Corp. (MNKD) report earnings?
Mannkind Corp. (MNKD) is schdueled to report earning on May 13, 2026, TBA (Confirmed).
What is Mannkind Corp. (MNKD) earnings time?
Mannkind Corp. (MNKD) earnings time is at May 13, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is MNKD EPS forecast?
MNKD EPS forecast for the fiscal quarter 2026 (Q1) is >-0.01.